Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Google Broadens Diabetes Reach With Dexcom Partnership

This article was originally published in Clinica

Executive Summary

DexCom Inc. is partnering with Google Inc. to develop smaller and cheaper continuous glucose meters (CGM) that would broaden their target market from a current focus on type 1 diabetes patients to the broader population. The partnership also may include using Google's cloud servers to collect and analyze glucose-meter data from patients to improve outcomes and reduce healthcare costs.

You may also be interested in...



New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech

Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.

‘Aspire To Abide By’ Advertising Laws Crucial For Direct Seller’s Defense Against FTC Complaint

In other finding at odds with previous court decisions, federal judge says direct seller Neora doesn’t have an “agency relationship” to its independent sales representatives and isn’t responsible for ad claims they post.

Direct Seller’s Data Counters FTC’s Pyramid Scheme Complaint Based On ‘Assumption’ About Sales

Ruling in Texas federal court on FTC complaint against Neora could serve as instructions for agency on how not to prosecute pyramid scheme allegations and for direct sellers about operating businesses so regulators find no hint of sales associates’ compensation plans based more on recruiting additional participants than on selling products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT102792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel